Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
37 hedge funds and large institutions have $36.5M invested in Viracta Therapeutics, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 8 closing their positions.
1,179% more call options, than puts
Call options by funds: $716K | Put options by funds: $56K
0% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 11
10% less funds holding
Funds holding: 41 → 37 (-4)
25% less capital invested
Capital invested by funds: $48.7M → $36.5M (-$12.1M)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$6.56M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
+$1.64M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$756K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$252K |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$224K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.13M |
| 2 |
SCM
Sio Capital Management
New York
|
-$913K |
| 3 |
Neuberger Berman Group
New York
|
-$576K |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$558K |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$350K |
VIRX Hedge Fund Activity: Q2 2017 in Review
37 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q2 2017, worth a combined $36.5M — down 25% from $48.7M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of VIRX and 4 opened new positions — a net loss of 4 holders — while 11 trimmed existing stakes and 11 added.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $6.56M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $2.13M sold.
- 37 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q2 2017, down from 41 in Q1 2017.
- Funds reported $36.5M of Viracta Therapeutics, Inc. Common Stock stock for Q2 2017, down 25% quarter-over-quarter.
- 4 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q2 2017 and 8 closed out, a net change of -4 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q2 2017 was Balyasny Asset Management, an estimated $6.56M added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q2 2017 was Cormorant Asset Management, an estimated $2.13M sold.
Based on aggregated 13F filings for Q2 2017.